"Bdaz, I don’t think it is unfair at all. If I have learned anything from investing in biotechs it is that when combining a new drug with multiple existing drugs, making the differentiation a pre-specified endpoint is almost done as a matter of due course."

Statin are all small molecule inhibitors of the HMG-CoA reductase enzyme. So statins are all the same class of drugs. If an investigational therapy like apabetalone is being tested in combination with differerent classes of drugs, then I think your point is valid. For example, for LDL-C lowering there are a few different classes of drugs (statins, PCSK9s, ezetimibe). However, if an investigational therapy is being tested in combination only with fellow members of the same class of drugs (all statins), it is quite uncommon in my opinion for there to be pre-specified analyses between sub-groups based on investigational therapy X different members of same class of drug. Based on your experience you cited, can you specifically tell us one clinical study that does this (other than BETonMACE) so we can take a look?

BearDownAZ